Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1186/s13722-015-0024-7

http://scihub22266oqcxt.onion/10.1186/s13722-015-0024-7
suck pdf from google scholar
25928069/?report=reader!4422150!25928069
unlimited free pdf from europmc25928069    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid25928069      Addict+Sci+Clin+Pract 2015 ; 10 (1): 8
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Designer drugs 2015: assessment and management #MMPMID25928069
  • Weaver MF; Hopper JA; Gunderson EW
  • Addict Sci Clin Pract 2015[Mar]; 10 (1): 8 PMID25928069show ga
  • Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.
  • |Alkaloids/pharmacology[MESH]
  • |Cannabinoids/pharmacology[MESH]
  • |Cognitive Behavioral Therapy[MESH]
  • |Counseling[MESH]
  • |Designer Drugs/adverse effects/*pharmacology[MESH]
  • |Hallucinogens/pharmacology[MESH]
  • |Humans[MESH]
  • |Hypnotics and Sedatives/therapeutic use[MESH]
  • |Monitoring, Physiologic[MESH]
  • |Patient Education as Topic[MESH]
  • |Psychotropic Drugs/adverse effects/*pharmacology[MESH]
  • |Substance Abuse Detection[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box